Skip to content
Eprosartan
Teveten (eprosartan) is a small molecule pharmaceutical. Eprosartan was first approved as Teveten on 1997-12-22. It is used to treat diabetic nephropathies, heart failure, hypertension, and left ventricular dysfunction in the USA. The pharmaceutical is active against type-1 angiotensin II receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
cardiovascular diseasesD002318
endocrine system diseasesD004700
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Eprosartan mesylate
Tradename
Company
Number
Date
Products
TEVETENAbbVieN-020738 DISCN1997-12-22
3 products, RLD
Hide discontinued
Eprosartan mesylate
+
Hydrochlorothiazide
Tradename
Company
Number
Date
Products
TEVETEN HCTAbbVieN-021268 DISCN2001-11-01
2 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
teveten hctNew Drug Application2012-01-03
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
diabetic nephropathiesEFO_0000401D003928—
heart failureEFO_0003144D006333I50
hypertensionEFO_0000537D006973I10
left ventricular dysfunction—D018487—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C09: Agents acting on the renin-angiotensin system
— C09C: Angiotensin ii receptor blockers (arbs), plain
— C09CA: Angiotensin ii receptor blockers (arbs), plain
— C09CA02: Eprosartan
— C09D: Angiotensin ii receptor blockers (arbs), combinations
— C09DA: Angiotensin ii receptor blockers (arbs) and diuretics
— C09DA02: Eprosartan and diuretics
HCPCS
No data
Clinical
Clinical Trials
14 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Allergic conjunctivitisD003233EFO_0007141H10.44———3—3
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atopic dermatitisD003876EFO_0000274L20——2——2
Allergic rhinitis perennialD012221EFO_1001417J30.89——2——2
Allergic rhinitis seasonalD006255EFO_0003956J30—11——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Allergic rhinitisD065631J30.9—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—4————4
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameEPROSARTAN
INNeprosartan
Description
Eprosartan is a member of the class of imidazoles and thiophenes that is an angiotensin II receptor antagonist used for the treatment of high blood pressure. It has a role as an antihypertensive agent, an angiotensin receptor antagonist, a xenobiotic and an environmental contaminant. It is a dicarboxylic acid, a member of imidazoles and a member of thiophenes.
Classification
Small molecule
Drug classangiotensin II receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1
Identifiers
PDB—
CAS-ID133040-01-4
RxCUI83515
ChEMBL IDCHEMBL813
ChEBI ID4814
PubChem CID5281037
DrugBankDB00876
UNII ID2KH13Z0S0Y (ChemIDplus, GSRS)
Target
Agency Approved
AGTR1
AGTR1
Organism
Homo sapiens
Gene name
AGTR1
Gene synonyms
AGTR1A, AGTR1B, AT2R1, AT2R1B
NCBI Gene ID
185
Protein name
type-1 angiotensin II receptor
Protein synonyms
Angiotensin II type-1 receptor, AT1 receptor, AT1AR, AT1BR, type-1B angiotensin II receptor
Uniprot ID
Q8TBK4
Mouse ortholog
Agtr1b (11608)
type-1 angiotensin II receptor B (P29755)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,041 documents
View more details
Safety
Black-box Warning
Black-box warning for: Teveten hct
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,063 adverse events reported
View more details